This study examined microglial marker expression patterns, specifically focusing on IBA1 low/negative microglia found in individuals with liver disease. The research investigated how systemic conditions like liver disease can affect microglial marker expression in the brain, providing insights into the relationship between peripheral pathology and central nervous system microglial function. This analysis contributes to understanding microglial heterogeneity in disease states.
EXPECTED OUTCOMES
## Primary Outcomes
**IBA1 Subset Prevalence**: IBA1 low/negative macrophages constitute 8-15% of total CD68+ cells in normal liver but increase to 20-35% in advanced fibrosis (F3-F4, p < 0.01). This suggests IBA1 downregulation marks a distinct macrophage activation state.
**Fibrogenic Correlation**: IBA1 low/negative subset frequency correlates with fibrosis stage (Spearman ρ = 0.62, p < 0.001) and hepatic collagen content (hydroxyproline assay, ρ = 0.55, p < 0.01). Suggests this subset may drive fibrogenesis.
## Secondary Outcomes
**Transcriptomic Signature**: IBA1 low/negative macrophages upregulate fibrogenic genes (ACTA2: +2.5-fold, COL1A1: +1.8-fold, TGFB1: +2.1-fold) and M2 markers (CD163: +3.0-fold, CD206: +2.2-fold) vs. IBA1 high subset, consistent with profibrotic macrophage phenotype.
**Spatial Preference**: IBA1 low/negative macrophages preferentially localize to fibrotic septa (within 50 μm of collagen I+ areas, OR = 2.8 vs. IBA1 high cells), supporting direct role in matrix deposition.
SUCCESS CRITERIA
## Primary Success Criteria
**Subset Identification**: IBA1 low/negative subset must be clearly distinguishable from IBA1 high subset via flow cytometry (distinct peaks with ≤15% overlap) and immunofluorescence (≤25th percentile intensity cutoff reproducible across runs).
**Disease Association**: IBA1 low/negative proportion must show significant increase in fibrosis (F2) vs. no fibrosis (F0) groups (≥15% absolute increase, p < 0.01).
## Secondary Success Criteria
**Transcriptomic Validation**: Fibrogenic gene expression (ACTA2, COL1A1, TGFB1) must be ≥1.5-fold higher in sorted IBA1 low vs. IBA1 high macrophages from the same patients, confirming functional specialization.
**Reproducibility**: Subset proportions must show ≤20% inter-batch variation across 3 independent staining runs on the same patient sample.
PROTOCOL
# Analysis of IBA1 Low/Negative Microglia in Liver Disease Patients Protocol
## Phase 1: Patient Recruitment and Liver Biopsy Collection (Days 1-30)
**Patient Cohort**: Recruit adult patients (n=80) undergoing percutaneous liver biopsy for clinical indication at tertiary hepatology center. Include disease groups: (a) non-alcoholic fatty liver disease (NAFLD, n=25), (b) alcoholic liver disease (ALD, n=20), (c) chronic hepatitis B/C (n=20), (d) normal liver histology (controls, n=15). Obtain written informed consent.
**Biopsy Processing**: Collect research cores (16G needle, ≥1.5 cm length) alongside clinical samples. Immediately snap-freeze in liquid nitrogen for molecular studies and place in RNAlater for RNA preservation. Process remaining tissue in OCT for immunohistochemistry.
**Clinical Data Collection**: Record demographics, BMI, metabolic syndrome criteria, MELD score, Child-Pugh class, liver enzymes (ALT, AST, ALP, GGT), and fibrosis stage (METAVIR, Brunt, or NASH-CRN scoring).
## Phase 2: Immunohistochemical Profiling of Macrophage Populations (Days 31-49)
**Multiplex Immunofluorescence**: Perform 7-color Opal multiplex (PerkinElmer) on frozen liver sections (5 μm). Stain sequence: IBA1 (1:200, Wako #019-19741), CD68 (1:100, Abcam #ab783), CD163 (1:100, Abcam #ab189981, M2 macrophage marker), CD86 (1:50, BD Biosciences #555664, M1 marker), DAPI, and one experimental marker per run. Image on Vectra 3.0.
**IBA1 Subset Analysis**: Using inForm software, segment liver macrophages as CD68+ cells. Subclassify as IBA1 high (>75th percentile), IBA1 intermediate, or IBA1 low/negative (<25th percentile). Quantify proportion of each subset within total CD68+ macrophages per patient.
**Spatial Analysis**: Map IBA1 subset distribution relative to: (a) fibrotic septa (collagen I staining), (b) portal tracts, (c) steatotic areas. Calculate proximity (distance to nearest fibrotic strand) for each subset.
## Phase 3: Transcriptomic and Functional Characterization (Days 50-70)
**qRT-PCR Array**: Sort IBA1 high vs. IBA1 low/negative macrophages from fresh liver tissue via magnetic bead separation (CD11b+ enrichment, then FACS based on IBA1 intensity). Extract RNA, run RT² qPCR Array Human Macrophage markers (Qiagen #PAHS-064ZA) covering 84 genes.
**Pathway Analysis**: Compare gene expression between IBA1 high and IBA1 low subsets. Focus on: (a) M1/M2 polarization markers, (b) fibrogenic genes (COL1A1, ACTA2, TGFB1), (c) inflammatory cytokines (IL1B, IL10, TNF). Calculate fold change and pathway enrichment.
**Correlation with Clinical Severity**: Correlate IBA1 subset proportions with fibrosis stage (METAVIR F0-F4), NAS score (NAFLD activity score), and clinical liver function tests. Use ordinal logistic regression for fibrosis stage as outcome.